Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M228,454Revenue $M51,752Net Margin (%)38.3Altman Z-Score3.2
Enterprise Value $M245,921EPS $8.0Operating Margin %19.6Piotroski F-Score6
P/E(ttm)11.7Beneish M-Score-2.3Pre-tax Margin (%)21.5Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %1.3Quick Ratio0.6Cash flow > EarningsN
Price/Sales4.45-y EBITDA Growth Rate %-0.6Current Ratio0.8Lower Leverage y-yY
Price/Free Cash Flow22.5y-y EBITDA Growth Rate %12.6ROA % (ttm)15.5Higher Current Ratio y-yN
Dividend Yield %2.8PEG--ROE % (ttm)27.3Less Shares Outstanding y-yY
Payout Ratio %66.0Shares Outstanding M2,415ROIC % (ttm)10.4Gross Margin Increase y-yN

Gurus Latest Trades with NVS

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVSDodge & Cox 2015-06-30 Reduce-0.19%$98.34 - $105.5
($102.32)
$ 94.59-8%Reduce 4.12%47,970,345
NVSKahn Brothers 2015-06-30 Reduce-0.05%$98.34 - $105.5
($102.32)
$ 94.59-8%Reduce 9.12%28,143
NVSTweedy Browne 2015-06-30 Reduce-0.02%$98.34 - $105.5
($102.32)
$ 94.59-8%Reduce 2.31%254,217
NVSKen Fisher 2015-06-30 Add0.01%$98.34 - $105.5
($102.32)
$ 94.59-8%Add 1.08%6,054,640
NVSMario Gabelli 2015-06-30 Reduce$98.34 - $105.5
($102.32)
$ 94.59-8%Reduce 15.35%8,330
NVSDodge & Cox 2015-03-31 Reduce-0.02%$91.67 - $103
($98.99)
$ 94.59-4%Reduce 0.58%50,032,795
NVSTweedy Browne 2015-03-31 Reduce-0.01%$91.67 - $103
($98.99)
$ 94.59-4%Reduce 2.19%260,217
NVSHOTCHKIS & WILEY 2015-03-31 Sold Out -0.0031%$91.67 - $103
($98.99)
$ 94.59-4%Sold Out0
NVSKen Fisher 2015-03-31 Reduce$91.67 - $103
($98.99)
$ 94.59-4%Reduce 0.29%5,990,224
NVSMario Gabelli 2015-03-31 Add$91.67 - $103
($98.99)
$ 94.59-4%Add 2.61%9,840
NVSRuane Cunniff 2014-12-31 Sold Out $85.02 - $96.65
($92.56)
$ 94.592%Sold Out0
NVSHOTCHKIS & WILEY 2014-09-30 Reduce-0.21%$85.25 - $94.8
($90.27)
$ 94.595%Reduce 98.51%9,646
NVSRuane Cunniff 2014-09-30 Buy $85.25 - $94.8
($90.27)
$ 94.595%New holding7,772
NVSHOTCHKIS & WILEY 2014-06-30 Reduce-0.52%$82.51 - $90.98
($87.73)
$ 94.598%Reduce 71.80%649,519
NVSDodge & Cox 2014-06-30 Add0.4%$82.51 - $90.98
($87.73)
$ 94.598%Add 10.04%51,102,219
NVSChris Davis 2013-09-30 Sold Out -0.01%$70.66 - $77.08
($73.84)
$ 94.5928%Sold Out0
NVSVanguard Health Care Fund 2013-06-30 Sold Out -0.2%$68.42 - $75.5
($72.61)
$ 94.5930%Sold Out0
NVSVanguard Health Care Fund 2013-03-31 Reduce-0.71%$63.3 - $71.32
($67.87)
$ 94.5939%Reduce 85.39%726,200
NVSKahn Brothers 2013-03-31 Reduce-0.1%$63.3 - $71.32
($67.87)
$ 94.5939%Reduce 21.03%33,456
NVSVanguard Health Care Fund 2012-12-31 Reduce-0.99%$58.97 - $63.96
($61.82)
$ 94.5953%Reduce 70.59%1,461,400
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVS is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Novartis Bioventures Ltd10% Owner 2014-09-22Buy325,000$15530.6view

Quarterly/Annual Reports about NVS:

    News about NVS:

    Articles On GuruFocus.com
    [email protected] Aug 26 2015 
    [email protected] Aug 26 2015 
    Valeant Pharmaceuticals' New Female Drug Aug 20 2015 
    Bill Frels' Stocks With Highest-Growing Yields Jun 26 2015 
    Bill Frels' Stocks With Growing Yields Jun 27 2015 
    Bristol-Myers Squibb Takes A Step Up On Cancer Drugs, But The Cost Tells A Different Story Jun 22 2015 
    Follow Bill Ackman in Valeant Pharmaceuticals Jun 19 2015 
    Billionaire George Soros Ups Two Stakes in First Quarter Jun 16 2015 
    Will GlaxoSmithKline Cut Its 6% Dividend? Jun 03 2015 
    Baxter Takes The Acquisition Route To Grow In The Oncology Segment May 14 2015 

    More From Other Websites
    Research and Markets: Investigation Report on China's Octreotide Market, 2010-2019 Sep 04 2015
    3:48 am Novartis receives EU approval for Farydak Sep 04 2015
    Big Pharma: The Moment of Dread Is Here Sep 03 2015
    Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S. Sep 03 2015
    Amgen (AMGN) Stock Falls as Novartis Begins Selling Biosimilar Version of Neupogen Sep 03 2015
    First biosimilar hits US Sep 03 2015
    Novartis to Begin Selling Copy of Amgen's Neupogen in U.S. Sep 03 2015
    Research and Markets: Investigation Report on China's Imatinib Mesylate (Novartis) Market 2010-2019 Sep 03 2015
    Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
    Novartis launches first U.S. 'biosimilar' drug at 15 pct discount Sep 03 2015
    The Next Blockbusters Could Be Balms For Aging Eyes Sep 03 2015
    Regeneron, Roche, Bayer, More Set Sights On Better Eye Drugs Sep 03 2015
    Novartis launches first biological copycat drug in US Sep 03 2015
    First Biosimilar Drug Goes on Sale in U.S., Challenging Amgen Sep 03 2015
    Novartis launches Neupogen copycat Zarxio in U.S. market Sep 03 2015
    Amgen, Novartis Team Up; Bone Drug Positive in Phase III Sep 02 2015
    Another Cambridge gene-editing startup raises millions in funding Sep 02 2015
    Amgen cannot stop imminent sale of Neupogen copycat -U.S. appeals court Sep 02 2015
    Novartis Closer to Selling Copy of Amgen's Neupogen Sep 02 2015
    Some leukemia patients see durable results from Novartis therapy Sep 02 2015

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK